Transition/Lilly's novel anti-diabetic passes Phase II study
This article was originally published in Scrip
Executive Summary
Transition Therapeutics/Lilly's novel experimental gastrin analogue TT-223 met its primary endpoint in a Phase IIb trial, significantly improving HbA1c levels in patients with type 2 diabetes.